Leiomyosarcoma
The present study is an open‑label, randomized, controlled, two‑arm multi‑center study of the efficacy of L19TNF treatment in combination with doxorubicin versus doxorubicin alone in metastatic leiomyosarcoma patients.
Phase 2 open‑label RCT assessing the safety and efficacy of the novel anti‑TNF fusion protein L19TNF combined with doxorubicin versus doxorubicin alone in patients with metastatic leiomyosarcoma.
Soft tissue sarcoma is a rare, aggressive malignancy with limited systemic options in metastatic disease; this trial evaluates a potential therapeutic combination that could improve response rates and survival.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- First-Line Chemotherapy Regimens for Advanced and Metastatic Leiomyosarcoma: Doxorubicin vs. Gemcitabine—A Systematic Review
- Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study
- Lineage-defined leiomyosarcoma subtypes emerge years before diagnosis and determine patient survival
- Immunotherapy-based salvage therapy in advanced soft tissue sarcoma after first-line chemotherapy: a retrospective single-center analysis with emphasis on undifferentiated pleomorphic sarcoma
- First-line treatment options for advanced leiomyosarcoma evaluated by propensity‑score matching